CLIENT LOGIN

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS:  Laura J. Esserman, MD, Read More

2020-06-15T18:01:56-07:00November 2nd, 2017|Clinical Validation, Esserman, Evidence, JAMA Oncol., JAMA Oncology, MammaPrint|
Read More

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Read More

2020-06-15T18:02:13-07:00November 1st, 2017|Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, van't Veer|
Read More

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep Read More

2020-06-15T18:02:53-07:00September 22nd, 2017|BluePrint, Evidence, Fatima, MammaPrint, Test Development|
Read More

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor–Positive Early Breast Cancer: Results of a Prospective Cohort Study

PUBLICATION: Journal of Clinical Oncology 35, no. 24 (August 20, Read More

2020-06-15T18:03:07-07:00August 20th, 2017|Clinical Validation, Evidence, Journal of Clinical Oncology, Kuijer, MammaPrint|
Read More

Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.

PUBLICATION: European Journal of Cancer. July 2017, Volume 79, Pages Read More

2020-06-15T18:40:28-07:00July 2nd, 2017|Aalders, Clinical Validation, European Journal of Cancer, Evidence, MammaPrint|
Read More

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer

PUBLICATION: Biomark Insights. 2016; 11: 139–146. doi: 10.4137/BMI.S38435 AUTHORS: Inès Read More

2020-06-15T18:43:57-07:00December 11th, 2016|Beumer, Biomarker Insights, Clinical Validation, Evidence, MammaPrint|
Read More

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. https://doi.org/10.1007/s10549-016-3949-y09. AUTHORS: Read More

2020-06-15T18:44:31-07:00August 27th, 2016|Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, Nunes|
Read More

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

PUBLICATION: N Engl J Med 2016; 375:717-729; DOI: 10.1056/NEJMoa1602253. AUTHORS: Read More

2020-06-15T18:44:47-07:00August 25th, 2016|Cardoso, Clinical Validation, Evidence, MammaPrint, MINDACT, NEJM|
Read More


Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

© 2022 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.

window.lintrk('track', { conversion_id: 8615804 });
Go to Top